Login / Signup

A novel Bayesian generative approach for estimating tumor dynamics from published studies.

Arya PourzanjaniSaurabh ModiJamie N ConnarnXinwen ZhangVijay V UpretiChih-Wei LinKhamir Mehta
Published in: CPT: pharmacometrics & systems pharmacology (2024)
Tumor growth inhibition (TGI) modeling attempts to describe the time course changes in tumor size for patients undergoing cancer therapy. TGI models present several advantages over traditional exposure-response models that are based explicitly on clinical end points and have become a popular tool in the pharmacometrics community. Unfortunately, the data required to fit TGI models, namely longitudinal tumor measurements, are sparse or often not available in literature or publicly accessible databases. On the contrary, common end points such as progression-free survival (PFS) and objective response rate (ORR) are directly derived from longitudinal tumor measurements and are routinely published. To this end, a Bayesian generative model relating underlying tumor dynamics to summary PFS and ORR data is introduced to learn TGI model parameters using only published summary data. The parameterized model can describe the tumor dynamics, quantify treatment effect, and account for differences in the study population. The utility of this model is shown by applying it to several published studies, and learned parameters are combined to simulate an in silico trial of a novel combination therapy in a novel setting.
Keyphrases
  • combination therapy
  • patients undergoing
  • cancer therapy
  • healthcare
  • free survival
  • systematic review
  • clinical trial
  • drug delivery
  • data analysis
  • machine learning
  • meta analyses
  • replacement therapy